RIVASTIGMINE TARTRATE- rivastigmine tartrate capsule

Država: Združene države Amerike

Jezik: angleščina

Source: NLM (National Library of Medicine)

Aktivna sestavina:

RIVASTIGMINE TARTRATE (UNII: 9IY2357JPE) (RIVASTIGMINE - UNII:PKI06M3IW0)

Dostopno od:

Golden State Medical Supply, Inc.

INN (mednarodno ime):

RIVASTIGMINE TARTRATE

Sestava:

RIVASTIGMINE 1.5 mg

Pot uporabe:

ORAL

Tip zastaranja:

PRESCRIPTION DRUG

Terapevtske indikacije:

Rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. Rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see Description (11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see Warnings and Precautions (5.2)]. Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)] . Pregnancy Category B   There are no adequate and well-controlled studies in pregnant women. Reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum r

Povzetek izdelek:

Rivastigmine tartrate capsules Rivastigmine tartrate capsules, USP 1.5 mg are hard gelatin capsules with yellow opaque body and yellow opaque cap, imprinted “APO R1.5” in black ink with white to off-white fill. They are supplied as follows: Bottles of 60 (NDC 60429-393-60) Rivastigmine tartrate capsules, USP 3 mg are hard gelatin capsules with orange opaque body and orange opaque cap, imprinted “APO R3” in black ink with white to off-white fill. They are supplied as follows: Bottles of 60 (NDC 60429-394-60) Rivastigmine tartrate capsules, USP 4.5 mg are hard gelatin capsules with red opaque body and red opaque cap, imprinted “APO R4.5” in black ink with white to off-white fill. They are supplied as follows: Bottles of 60 (NDC 60429-395-60) Rivastigmine tartrate capsules, USP 6 mg are hard gelatin capsules with orange opaque body and red opaque cap, imprinted “APO R6” in black ink with white to off-white fill. They are supplied as follows: Bottles of 60 (NDC 60429-396-60) Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Store in a tight container.

Status dovoljenje:

Abbreviated New Drug Application

Lastnosti izdelka

RIVASTIGMINE TARTRATE- RIVASTIGMINE TARTRATE CAPSULE
GOLDEN STATE MEDICAL SUPPLY, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
RIVASTIGMINE TARTRATE CAPSULES.
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
RIVASTIGMINE TARTRATE CAPSULES
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
RIVASTIGMINE TARTRATE CAPSULES.
RIVASTIGMINE TARTRATE CAPSULES, FOR ORAL USE
INITIAL U.S. APPROVAL: 2000
INDICATIONS AND USAGE
Rivastigmine tartrate is an acetylcholinesterase inhibitor indicated
for treatment of:
1. Mild to moderate dementia of the Alzheimer’s type (1.1)
2. Mild to moderate dementia associated with Parkinson’s disease
(1.2)
DOSAGE AND ADMINISTRATION
Alzheimer’s Disease
1. Initiate treatment with 1.5 mg twice a day
2. After a minimum of 2 weeks, if tolerated, increase dose to 3 mg
twice a day and further to 4.5 mg twice a day and 6 mg
twice a day if tolerated with a minimum of 2 weeks at each dose ( 2.1)
Parkinson’s Disease Dementia
1. Initiate treatment with 1.5 mg twice a day
2. After a minimum of 4 weeks, if tolerated, increase dose to 3 mg
twice a day and further to 4.5 mg twice a day and 6 mg
twice a day if tolerated with a minimum of 4 weeks at each dose ( 2.2)
Rivastigmine tartrate should be taken with meals in divided doses in
the morning and evening. ( 2.1, 2.2) Rivastigmine
tartrate capsules may be interchanged at equal doses ( 2.4)
DOSAGE FORMS AND STRENGTHS
1. Capsules: 1.5 mg, 3 mg, 4.5 mg, or 6 mg (3.1)
CONTRAINDICATIONS
1. Known hypersensitivity to rivastigmine, other carbamate derivatives
or other components of the formulation (4)
2. History of application site reaction with rivastigmine transdermal
patch suggestive of allergic contact dermatitis, in the
absence of negative allergy testing (4, 5.2)
WARNINGS AND PRECAUTIONS
1. Gastrointestinal adverse reactions may include significant nausea,
vomiting, diarrhea, anorexia/decreased appetite, and
weight loss, and may necessitate treatment interruption. Dehydration
may result from prolonged vomiting or diar